Clinical Trials
CDG Therapeutics has recently completed two Phase I trials of our lead compound, p28 (NSC7451040), one in adult patients with recurrent, refractory and progressive solid tumors and another in pediatric patients with refractory, progressive, central nervous system (CNS) tumors. Patients did not exhibit dose-limiting toxicities (DLTs), significant adverse events or an immune response (IgG) to p28. Evidence of anti-tumor activity, in adult and pediatric patients, indicates a highly favorable therapeutic index and demonstrates proof of concept for this new class of non-HDM2-mediated peptide inhibitors of p53 ubiquitination.